Sight Sciences, Inc. (SGHT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Sight Sciences: Signs Of Progress, But Plenty Of Work Remains
Sight Sciences is a cautious 'buy,' as recent reimbursement wins and product momentum support a positive outlook, offset by liquidity pressures and ongoing reimbursement and utilization challenges. SGHT's OMNI Ultra Surgical System launch and updated TearCare label provide incremental adoption tailwinds, but procedure costs/reimbursement and surgeon preference remain key hurdles. Q2 revenue grew 20% with strong dry eye business acceleration, improved gross margins, and reduced cash burn; Aetna coverage adds 25 million insured lives to the glaucoma business.
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sight Sciences Q2 Earnings Call Highlights
Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Sight Sciences (SGHT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.28 per share a year ago.
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
